Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 18:354:i4189.
doi: 10.1136/bmj.i4189.

Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study

William Fleischman  1 , Shantanu Agrawal  2 , Marissa King  3 , Arjun K Venkatesh  4 , Harlan M Krumholz  5 , Douglas McKee  6 , Douglas Brown  2 , Joseph S Ross  7
Affiliations

Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study

William Fleischman et al. BMJ. .

Abstract

Objective: To examine the association between payments made by the manufacturers of pharmaceuticals to physicians and prescribing by physicians within hospital referral regions.

Design: Cross sectional analysis of 2013 and 2014 Open Payments and Medicare Part D prescribing data for two classes of commonly prescribed, commonly marketed drugs: oral anticoagulants and non-insulin diabetes drugs, overall and stratified by physician and payment type.

Setting: 306 hospital referral regions, United States.

Participants: 45 949 454 Medicare Part D prescriptions written by 623 886 physicians to 10 513 173 patients for two drug classes: oral anticoagulants and non-insulin diabetes drugs.

Main outcome measures: Proportion, or market share, of marketed oral anticoagulants and non-insulin diabetes drugs prescribed by physicians among all drugs in each class and within hospital referral regions.

Results: Among 306 hospital referral regions, there were 977 407 payments to physicians totaling $61 026 140 (£46 174 600; €54 632 500) related to oral anticoagulants, and 1 787 884 payments totaling $108 417 616 related to non-insulin diabetes drugs. The median market share of the hospital referral regions was 21.6% for marketed oral anticoagulants and 12.6% for marketed non-insulin diabetes drugs. Among hospital referral regions, one additional payment (median value $13, interquartile range, $10-$18) was associated with 94 (95% confidence interval 76 to 112) additional days filled of marketed oral anticoagulants and 107 (89 to 125) additional days filled of marketed non-insulin diabetes drugs (P<0.001). Payments to specialists were associated with greater prescribing of marketed drugs than payments to non-specialists (212 v 100 additional days filled per payment of marketed oral anticoagulants, 331 v 114 for marketed non-insulin diabetes drugs, P<0.001). Payments for speaker and consulting fees for non-insulin diabetes drugs were associated with greater prescribing of marketed drugs than payments for food and beverages or educational materials (484 v 110, P<0.001).

Conclusions and study limitations: Payments by the manufacturers of pharmaceuticals to physicians were associated with greater regional prescribing of marketed drugs among Medicare Part D beneficiaries. Payments to specialists and payments for speaker and consulting fees were predominantly associated with greater regional prescribing of marketed drugs than payments to non-specialists or payments for food and beverages, gifts, or educational materials. As a cross sectional, ecological study, we cannot prove causation between payments to physicians and increased prescribing. Furthermore, our findings should be interpreted only at the regional level. Our study is limited to prescribing by physicians and the two drug classes studied.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: WF serves as a volunteer researcher at the Centers for Medicare and Medicaid Services (CMS), the agency that administers the Open Payments program. SA and DB worked at CMS at the time of writing. AKV, HMK, and JSR receive support through Yale University from CMS to develop and maintain performance measures that are used for public reporting. HMK and JSR receive support through Yale University from Medtronic and Johnson and Johnson to develop methods for the sharing of clinical trial data, from the Blue Cross Blue Shield Association to better understand the generation of medical technology evidence, and from the Food and Drug Administration to develop methods for post-market surveillance of medical devices.

Figures

None
Fig 1 Distribution of payments by pharmaceutical manufacturers to physicians, and physician prescribing of marketed drugs among Medicare Part D beneficiaries for oral anticoagulants, by hospital referral region. Payments per 1000 person years of Part D coverage for oral anticoagulants (top panel); market share (%) of marketed oral anticoagulants (bottom panel)
None
Fig 2 Distribution of payments by pharmaceutical manufacturer to physicians, and physician prescribing of marketed drugs among Medicare Part D beneficiaries for non-insulin diabetes drugs, by hospital referral region. Payments per 1000 person years of Part D coverage for non-insulin diabetes drugs (top panel); market share (%) of marketed non-insulin diabetes drugs (bottom panel)
See this image and copyright information in PMC

References

    1. Centers for Medicare & Medicaid Services. Open Payments Data Summary. OpenPaymentsData.CMS.gov https://openpaymentsdata.cms.gov/summary (accessed 2 Aug 2016).
    1. Austad KE, Avorn J, Franklin JM, Kowal MK, Campbell EG, Kesselheim AS. Changing interactions between physician trainees and the pharmaceutical industry: a national survey. J Gen Intern Med 2013;28:1064-71. 10.1007/s11606-013-2361-0 pmid:23444007. - DOI - PMC - PubMed
    1. Halperin EC, Hutchison P, Barrier RC Jr. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. Int J Radiat Oncol Biol Phys 2004;59:1477-83. 10.1016/j.ijrobp.2004.01.052 pmid:15275735. - DOI - PubMed
    1. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001;110:551-7. 10.1016/S0002-9343(01)00660-X pmid:11347622. - DOI - PubMed
    1. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?JAMA 2000;283:373-80. 10.1001/jama.283.3.373 pmid:10647801. - DOI - PubMed